Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
FIGNL1 CRISPR/Cas9 KO Plasmid (h): sc-410087
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- FIGNL1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the FIGNL1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: FIGNL1 Antibody (A-4): sc-398264
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
FIGNL1 CRISPR/Cas9 KO Plasmid (h) | sc-410087 | 20 µg | $397.00 |
Overview
FIGNL1 (fidgetin-like 1) encodes an AAA+ ATPase implicated in the regulation of DNA repair and genome maintenance through interactions with homologous recombination machinery. The protein has been linked to control of RAD51 filament dynamics and DNA end processing, connecting it to pathways that resolve replication-associated lesions and double-strand breaks. By influencing recombination outcomes and chromosome stability, FIGNL1 contributes to cell-cycle progression and faithful segregation of genetic material. Dysregulated FIGNL1 activity or expression has been associated with altered DNA damage responses observed in cancer biology and other contexts where genomic instability is a key feature.
FIGNL1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the FIGNL1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the FIGNL1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the FIGNL1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish FIGNL1 protein expression.
This CRISPR knockout system enables efficient generation of FIGNL1-deficient cell models for investigation of FIGNL1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting FIGNL1 exon(s) critical for FIGNL1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple FIGNL1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by FIGNL1 CRISPR/Cas9 KO Plasmid (h) and FIGNL1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the FIGNL1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by FIGNL1 HDR Plasmid (h) and FIGNL1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by FIGNL1 homology arms to support homology-directed repair at defined FIGNL1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.